ALL.SPACE Awards $8.2M Production Order to Sivers Semiconductors …
QTREX Awarded Government Grant to Advance the World’s First Nativ…
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal…
Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at A…
NIO Inc. Responds to the U.S. Department of Defense “Chinese Mili…
Hyperscale Data, Inc. Announces Preliminary Results for Tender Of…
ALL.SPACE Awards $8.2M Production Order to Sivers Semiconductors …
QTREX Awarded Government Grant to Advance the World’s First Nativ…
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal…
Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at A…
NIO Inc. Responds to the U.S. Department of Defense “Chinese Mili…
Hyperscale Data, Inc. Announces Preliminary Results for Tender Of…
ENvue Medical (NASDAQ: FEED) launched Ask Oscar, an AI-powered training platform for its ENvue Navigation feeding tube system. The tool lets clinicians train independently with real-time guidance and performance feedback, aiming to accelerate platform adoption and create scalable recurring revenue, while forming a foundation for future robotic-assisted ENvue Drive applications.
A peer-reviewed study of the ENvue Navigation Platform reported zero lung placements in 531 procedures, a 67% drop in ventilator-associated pneumonia, a 4,320% rise in post-pyloric feeding access, over 350 nursing hours saved annually and more than $1.5 million in annual cost avoidance in one health system.
AI-generated analysis. Not financial advice.
Following this news, FEED has gained 25.86%, reflecting a significant positive market reaction. Argus tracked a peak move of +64.0% during the session. Our momentum scanner has triggered 19 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $1.03. This price movement has added approximately $989K to the company’s valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
No peers from the Medical Devices group appeared in the momentum scanner, pointing to a stock-specific move rather than a sector-wide rotation.
Recent headlines have mostly been positive, yet the stock more often traded down on these news events than up.
Over the past month, ENvue reported multiple positive developments: contract renewal across a 12-hospital system, new ICU deployment expanding its footprint to 40 U.S. hospitals, and publication of an independent multi-hospital study showing safety and cost benefits. It also added a cannabinoid delivery patent. Despite this, price reactions have been mixed, with several selloffs after favorable updates, framing today’s AI training-platform launch against a backdrop of cautious trading.
The stock is surging +25.9% following this news. A strong positive reaction would align with the company’s narrative of building an AI-enabled platform on top of its ENvue Navigation system. Recent history shows mixed price responses to good news, so any move above $0.79 could reflect shifting sentiment toward scaling potential from Ask Oscar and its link to ENvue Drive. Investors would still need to watch execution and utilization across the 40-hospital base.
AI-generated analysis. Not financial advice.
AI-based platform, ‘Ask Oscar™’, to accelerate adoption of ENvue’s Navigation Platform and enable clinicians to train independently and reduce implementation barriers
See Ask Oscar in action: https://envuemed.com/ask-oscar/#video
TYLER, Texas, June 09, 2026 (GLOBE NEWSWIRE) — ENvue Medical (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today introduced ‘Ask Oscar™’, a new AI-powered training platform designed to address one of the biggest barriers to adoption of medical technology: training. The platform marks the Company’s transformation from a medical device maker into an AI platform company, with Ask Oscar as the first product to carry that vision. In addition to accelerating revenue in the short-term, the Company’s AI platform can rapidly integrate into its patent-pending robotic feeding tube solution, ENvue Drive.
AI Capabilities Can Accelerate Revenue
By enabling nurses, dietitians and other clinicians to train on their own schedule, ENvue believes Ask Oscar can significantly accelerate implementation of the ENvue Navigation Platform across both existing and prospective customer accounts.
Importantly, Ask Oscar is expected to be commercially available within the coming months and will be offered across ENvue’s growing installed customer base, creating a scalable recurring revenue opportunity for the Company.
“We believe that Ask Oscar changes the economics of how we scale and opens a new, recurring revenue stream across our existing and prospective hospital customers,” said Doron Besser, Chief Executive Officer of ENvue Medical.
Ask Oscar Addresses a Major Healthcare Barrier: Training
“One of the biggest barriers to scaling any medical technology is training,” said Doron Besser, Chief Executive Officer of ENvue.
Training remains one of the most significant bottlenecks in healthcare technology implementation as hospitals contend with increasing staffing pressures, growing workloads and ongoing challenges coordinating training across multiple shifts and clinical departments. Ask Oscar was developed to help hospitals support nurses, dietitians and other clinicians through training, skill reinforcement and procedural practice by providing real-time guidance and feedback whenever and wherever training is needed – without the need for on-site specialists.
Built upon ENvue’s existing navigation and training infrastructure, Ask Oscar allows clinicians to practice, reinforce and improve feeding tube placement skills through an interactive training environment that provides real-time guidance and objective performance feedback.
The platform continuously monitors user performance during training sessions, detects procedural deviations and provides immediate corrective guidance. Clinicians can practice repeatedly at their own pace without requiring a clinical educator to be physically present during every training session, helping hospitals standardize training, reduce implementation barriers and accelerate adoption.
Foundational Technology that Goes Beyond Training
While the immediate objective is to help clinicians learn faster and help hospitals implement ENvue more efficiently, the Company believes the technology foundation behind Ask Oscar extends beyond training.
Every training session performed within Ask Oscar is measured, analyzed and transformed into actionable feedback. By digitizing and understanding the feeding tube placement procedure itself, the Company believes that Ask Oscar establishes an intelligence layer that can support future applications across the ENvue ecosystem.
This includes technologies associated with ENvue Drive, the Company’s previously announced robotic-assisted feeding tube placement initiative. While Ask Oscar’s first application is training and adoption acceleration, the underlying platform creates opportunities for future intelligent guidance, advanced procedural assistance and robotic-assisted applications.
The launch of Ask Oscar follows the recent publication of an independent peer-reviewed study in Critical Care Nurse demonstrating significant clinical and operational benefits associated with the ENvue Navigation Platform, including zero lung placements across 531 consecutive procedures, a
Together, ENvue’s growing body of clinical evidence and Ask Oscar’s ability to support scalable training create a powerful framework for accelerating adoption across hospital systems.
See ‘Ask Oscar’ in action:
ENvue has released a video demonstration showing Ask Oscar guiding a simulated training procedure in real time. The video demonstrates how the platform can provide consistent, on-demand training support wherever training is needed.
About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to, statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com
Media Contact:
KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
envue@kcsa.com
Continue reading with these related stories
© 2020-2026 StockTitan.net – Your Edge is Information
Information only. Not investment advice.
